Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus M ZOLE 7 DUAL PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus M ZOLE 7 DUAL PACK.
FULVICIN P/G 165 vs M-ZOLE 7 DUAL PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
M-ZOLE 7 DUAL PACK contains miconazole, an imidazole antifungal that inhibits fungal lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity, and increasing permeability, leading to cell death.
165 mg orally once daily.
Adults: One vaginal tablet (containing 500 mg metronidazole and 150 mg miconazole nitrate) inserted vaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
Terminal half-life approximately 48–72 hours. Prolonged in renal impairment (up to 72–120 hours in ESRD), requiring dose adjustment.
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Primarily renal (80% unchanged drug, 20% as metabolites); biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antifungal
Antifungal